6815eba1-06e5-46d6-ad4b-e4132b5d1638
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 54.280629705681
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.620
- TNFA_SIGNALING_VIA_NFKB+0.580
- IL6_JAK_STAT3_SIGNALING+0.570
- INFLAMMATORY_RESPONSE+0.560
- ANGIOGENESIS+0.500
- ALLOGRAFT_REJECTION+0.480
- INTERFERON_GAMMA_RESPONSE+0.460
- COMPLEMENT+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- IL2_STAT5_SIGNALING+0.390
Top 10 suppressed
- MITOTIC_SPINDLE-0.390
- G2M_CHECKPOINT-0.380
- WNT_BETA_CATENIN_SIGNALING-0.380
- MYC_TARGETS_V2-0.320
- E2F_TARGETS-0.280
- HEDGEHOG_SIGNALING-0.250
- NOTCH_SIGNALING-0.180
- PANCREAS_BETA_CELLS-0.170
- ESTROGEN_RESPONSE_EARLY-0.160
- BILE_ACID_METABOLISM-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-5049-01A-01R-1628-07 | — | cohortA1 | 0.890 |
| 2 | a552cdf6.4113.4da4.8e5d.2f3d5555c74e | — | cohortMD2 | 0.889 |
| 3 | 52472301-36c6-4c99-97bd-b016d8a282d6 | — | — | 0.885 |
| 4 | TCGA-D8-A1Y2-01A-11R-A157-07 | — | C | 0.872 |
| 5 | 185b401a-bdc4-46b9-b2a5-7a66938f28f2 | — | — | 0.863 |
| 6 | SRR5088906 | — | — | 0.854 |
| 7 | MDT-AP-2021 | Med | Medulloblastoma | 0.853 |
| 8 | 17-026K4_Bladder | — | — | 0.849 |
| 9 | 27871087-0449-4f04-bc72-a975681a198a | — | — | 0.849 |
| 10 | MNG439 | — | — | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.620 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.580 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.570 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.560 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.390 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| HYPOXIA | 0.380 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |